Press release content from Business Wire. The AP news staff was not involved in its creation.
Matthew During, M.D., Ph.D. to Join the Scientific Advisory Board of Brooklyn ImmunoTherapeutics
April 26, 2021 GMT
BROOKLYN, N.Y. (BUSINESS WIRE) Apr 26, 2021
Brooklyn ImmunoTherapeutics, Inc. (NYSE American: BTX) (“Brooklyn”), a biopharmaceutical company focused on exploring the role that cytokine-based therapy can have in treating patients with cancer, today announced the appointment of Matthew During, M.D., Ph.D. to the Company’s Scientific Advisory Board, effective April 26, 2021.
Dr. During is a Harvard, MIT and Yale trained neuroscientist. He has served for 9 years as a member of the faculty of Yale as Professor of Neurosurgery, and as a Professor at Thomas Jefferson, Cornell, and Ohio State Universities. Dr. During was a pioneer in the use of viral vectors for neurological disorders, and was the first to carry out gene transfer into the brain of a human child. Dr. During
Press release content from Business Wire. The AP news staff was not involved in its creation.
Howard J. Federoff, MD, PhD Appointed Chief Executive Officer of Brooklyn ImmunoTherapeutics, Inc.
April 6, 2021 GMT
BROOKLYN, N.Y. (BUSINESS WIRE) Apr 6, 2021
Brooklyn ImmunoTherapeutics, Inc. (NYSE American: BTX) (“Brooklyn” or “the Company”), a biopharmaceutical company focused on exploring the role that cytokine-based therapy can have in treating patients with cancer, today announced the appointment of Howard J. Federoff, M.D., Ph.D., as Chief Executive Officer and President and a director as of 16 April 2021. Dr. Federoff succeeds Ronald Guido who was serving as Interim CEO and will remain on Brooklyn’s management team as Chief Development Officer.